Results 1 to 10 of about 76,984 (297)

Plasma Versus Whole Blood Tacrolimus Concentrations and Health-Related Quality of Life in Kidney Transplant Recipients [PDF]

Pharmaceutics
Background/Objectives: Tacrolimus dosing traditionally relies on therapeutic drug monitoring in whole blood, while assessment in plasma may better reflect its effect and reveal overdosing impacting health-related quality of life (HRQoL). Methods: In this
Svea Nolte, J. Casper Swarte, Tim J. Knobbe, Ilja M. Nolte, Tanja R. Zijp, Harmen R. Moes, Marco van Londen, Niels L. Riemersma, Johannes R. Björk, Rinse K. Weersma, Gea Drost, Stefan P. Berger, Daan J. Touw, Stephan J. L. Bakker   +13 more
doaj   +2 more sources

Comparing tacrolimus level monitoring in peripheral blood mononuclear cells and whole blood within one year after kidney transplantation: a single-center, prospective, observational study [PDF]

Frontiers in Pharmacology
BackgroundTacrolimus, a key immunosuppressant for kidney transplant recipients, is traditionally monitored through whole-blood trough concentrations. However, this approach may not accurately reflect lymphocyte tacrolimus levels, limiting its predictive ...
Jia You, Jia You, Jia You, Rui Chen, Rui Chen, Yuhui Chai, Xue Wang, Wenmin Xie, Yunyun Yang, Kaile Zheng, Kaile Zheng, Kaile Zheng, Lizhi Chen, Zhuo Wang, Xuebin Wang, Xuebin Wang, Xuebin Wang   +16 more
doaj   +2 more sources

Tacrolimus Intrapatient Variability After Switching From Immediate or Prolonged-Release to Extended-Release Formulation, After an Organ Transplantation

Frontiers in Pharmacology, 2021
Background and Purpose: Several formulations of tacrolimus are available, but evidence of the benefit of changing to the most recent formulations is lacking. Tacrolimus intra-patient variability (tacrolimus IPV) is an emerging risk factor associated with
Arnaud Del Bello, Arnaud Del Bello, Arnaud Del Bello, Clotilde Gaible, Nathalie Longlune, Anne-Laure Hebral, Laure Esposito, Peggy Gandia, Peggy Gandia, Nassim Kamar, Nassim Kamar, Nassim Kamar   +11 more
doaj   +1 more source

Human kidney organoids model the tacrolimus nephrotoxicity and elucidate the role of autophagy [PDF]

The Korean Journal of Internal Medicine, 2021
Background/Aims Tacrolimus has been used as an immunosuppressive agent in organ transplantation. Despite the therapeutic benefits, tacrolimus’s use is limited due to its nephrotoxicity.
Jin Won Kim, Sun Ah Nam, Eunjeong Seo, Jong Young Lee, Dohui Kim, Ji Hyeon Ju, Sun Woo Lim, Hong Lim Kim, Hyung Wook Kim, Chul Woo Yang, Jin Kim, Dong Sung Kim, Yong Kyun Kim   +12 more
doaj   +1 more source

A randomized crossover study comparing different tacrolimus formulations to reduce intrapatient variability in tacrolimus exposure in kidney transplant recipients

Clinical and Translational Science, 2022
A high intrapatient variability (IPV) in tacrolimus exposure is a risk factor for poor long‐term outcomes after kidney transplantation. The main objective of this trial was to investigate whether tacrolimus IPV decreases after switching patients from ...
Kim L. W. Bunthof, Linda Al‐Hassany, Gizal Nakshbandi, Dennis A. Hesselink, Ron H. N. vanSchaik, Marc A. G. J. ten Dam, Marije C. Baas, Luuk B. Hilbrands, Teun vanGelder   +8 more
doaj   +1 more source

Tacrolimus monitoring in hair samples of kidney transplant recipients

Frontiers in Medicine, 2023
BackgroundCalcineurin inhibitors, including tacrolimus, remain a cornerstone of immunosuppressive therapy after kidney transplantation. However, the therapeutic window is narrow, and nephrotoxic side effects occur with overdose, while the risk of ...
Alexander Born, Federica Bocchi, Christian Kuhn, Ursula Amstutz, Markus R. Baumgartner, Daniel Sidler   +5 more
doaj   +1 more source

Tacrolimus-induced neurotoxicity from bipolar disorder to status epilepticus under the therapeutic serum level: a case report

BMC Neurology, 2021
Background Tacrolimus is a macrolide immunosuppressant widely used to prevent rejection after solid organ transplantation. In general, adverse events of tacrolimus occur more often as the concentration of tacrolimus in the blood increases.
Bora Jin, Ga Yeon Kim, Sang-Myung Cheon
doaj   +1 more source

Clinical association between tacrolimus intra-patient variability and liver transplantation outcomes in patients with and without hepatocellular carcinoma

Scientific Reports, 2022
Tacrolimus is the mainstay of immunosuppression in liver transplantation to prevent rejection. However, the clinical use of tacrolimus is complicated by its narrow therapeutic window and significant intra-patient variability (IPV). High tacrolimus IPV is
Hyun Jeong Kim, Juhan Lee, Jae Geun Lee, Dong Jin Joo, Myoung Soo Kim   +4 more
doaj   +1 more source

Intravenous tacrolimus is a superior induction therapy for acute severe ulcerative colitis compared to oral tacrolimus

BMC Gastroenterology, 2021
Background Intravenous corticosteroid is the mainstay for managing acute severe ulcerative colitis, but one-third of patients do not respond to intravenous corticosteroid.
Hiromichi Shimizu, Toshimitsu Fujii, Kenji Kinoshita, Ami Kawamoto, Shuji Hibiya, Kento Takenaka, Eiko Saito, Masakazu Nagahori, Kazuo Ohtsuka, Mamoru Watanabe, Ryuichi Okamoto   +10 more
doaj   +1 more source

A Case of Tacrolimus Maculopathy

Clinics and Practice, 2022
(1) Background: Tacrolimus is an immunosuppressive agent commonly used in the management of solid organ allogeneic transplants in the prevention of rejection. Serious ophthalmic adverse effects with Tacrolimus have been reported in the literature, which includes cortical blindness and optic neuropathy.
Martina Santarelli, Marco Zeppieri, Carlo Salati   +2 more
openaire   +3 more sources